-+ 0.00%
-+ 0.00%
-+ 0.00%

Immutep to Present IMP761 Phase I Trial Data at ACR Convergence 2026

PUBT·10/18/2026 23:52:20
Listen to the news
Immutep to Present IMP761 Phase I Trial Data at ACR Convergence 2026
  • Immutep will present Phase 1 data on IMP761 at ACR Convergence in Orlando on November 10, 2026, following late-breaking abstract acceptance.
  • The first-in-human trial evaluates the immunosuppressive LAG-3 agonist antibody in healthy volunteers using a randomized, placebo-controlled, double-blind design.
  • Initial interim results were presented at the EULAR 2026 Congress in June 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.